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Introduction
Myasthenia gravis (MG) is a disorder of neuromus-
cular transmission resulting from either a defi-
ciency or functional disorder of the nicotinic
acetylcholine receptors (AChRs) as in congenital
MG or an autoimmune attack against AChRs re-
sulting in depletion of receptors in acquiring MG,
and the result is muscle weakness (Webb et al.,
1997). There are 3 types of the clinical syndrome
of MG: 1) focal MG (FMG) with muscle weakness
restricted to specific groups of pharyngeal,
esophageal, laryngeal, or facial muscles; 2) gener-
alized MG with exercise induced appendicular
muscle weakness and megaesophagus; 3) acute ful-
minating MG that involves a rapid onset of appen-
dicular muscle weakness, dyspnea, and collapse
(Moffet, 2007). In almost every aspect, acquired
canine MG is remarkably similar to the analogous
disease of human beings (Dewey et al. 1999). The
tendency for canine MG to develop megaesopha-
gus and aspiration pneumonia is present in 85% of
canine cases of MG, due to the striated musculature
in the canine esophagus (Shelton, 2002). Aspiration
pneumonia is the main reason for death and eu-
thanasia in acquiring MG dogs with megaesopha-
gus (Dewey et al. 1999). The diagnosis of FMG is
based on demonstration of serum autoantibodies to
muscle AChRs and distinguishing FMG from other
causes of canine megaesophagus (Webb et al.,
1997). In the present paper, we describe FMG in
two dogs with different time of recovered megae-
sophagus. 
Case History
A 2-years-3-months-old, 9.58 kg male French bull-
dog (Case 1) was referred to Gifu University teach-
ing animal hospital with 3 week history of
regurgitation. On presentation the dog showed a
good health condition with rectal temperature
39.4°C, the heart rats 80 times/min. Hematology
and serum biochemical profile revealed no abnor-
malities. Thoracic radiographic examination re-
vealed megaesophagus and for confirmation
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Abstract
Two dogs were presented with history of regurgitation. Both dogs were diagnosed with focal myasthenia gravis (FMG). Tho-
racic radiography was consisted with megaesophagus. Acetylcholine receptors (AChRs) antibody titer was positive. Both
dogs were treated with pyridostigmine bromide as sole treatment. One case rapidly resolved with the recovery of the esoph-
agus, while the other case even the AChRs antibody titer was normalized after 60 days but the clinical remission was occurred
after long time. This report suggested that clinical signs of FMG were resolved, but we can’t predict the time required, ad-
ditionally, pyridostigmine bromide might be effective for palliation of symptoms.
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barium swallow had been performed (Fig. 1).
Serum sample was sent to determine the anti-
AChRs antibody concentration (IDEXX Laborato-
ries, Tokyo). The differential diagnoses for the
underlying diseases causing megaesophagus were
performed as the following: thyroid hormones con-
centration, ACTH stimulation test and the anti-nu-
clear antibody for hypothyroidism,
hypoadrenocorticism and systemic lupus erythre-
matousus respectively (Table 1). There was no ev-
idence of muscle or joint pain, or other systemic
diseases. From the previous data the case was sus-
pected to be FMG. The treatment course was
started with 0.5 mg/kg of the pyridostigmine bro-
mide BID, PO. The low dose was chosen to mini-
mize the risk of a cholinergic crisis. The owner was
instructed to feed small and frequent meals from a
height and to hold the dog in vertical position for
10 minutes after feeding to minimize regurgitation.
On 25th day the result of AChRs autoantibodies
titer was 1.04 nmol/L (reference value 0.6 nmol/L)
and so the dose of pyridostigmine bromide was in-
creased to 2 mg/kg TID (Batmaz et al., 1998). Dur-
ing the follow up the dog condition was
re-evaluated by the response to treatment dose, fre-
quency of vomiting (Fig. 2), anti-AChRs antibody
titer and the degree of megaesophagus by radi-
ographic examination. It was observed that the fre-
quency of vomiting was increased after the dose of
2 mg/kg pyridostigmine bromide and we suspected
that related to pyridostigmine side effect and so the
medication was stopped on the 39th day. During
that time, other adverse effects included the mild
salivation and soft feces. The medication was re-
sumed again on the 51st day with 0.5 mg/kg pyri-
dostigmine bromide. A recheck serum anti-AChRs
antibody titer was normal (< 0.6 nmol/L) on the
day 60th, 135th, and 241st. On the day 345th, the
fluoroscopic examination of the chest showed that
the esophagus was returned to its normal condition.
Eighteen months later, the dog continued to do very
well, and the physical examination and biochem-
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Table 1. Screening examinations of the two dogs
NE: not examined
Fig. 1. Right recumbency contrast thoracic radiograph of case 1. The existence of the megaesophagus is shown.
istry panel remained normal.
A 7-years-old, 3.32 kg female Yorkshire Terrier
dog (Case 2) was referred with 1-week history of
regurgitation. On presentation the animal showed
good heath condition. Hematology and serum bio-
chemical profile revealed no abnormalities. Tho-
racic radiograph revealed megaesophagus (Figure
1). Serum examination of autoantibodies to muscle
AChRs, thyroid hormones concentration, ACTH
stimulation test and anti-nuclear antibody was car-
ried out (Table 1). From the previous data the case
was diagnosed as FMG. The dog was treated with
pyridostigmine bromide at a dose of 0.5 mg/kg BID
orally. It was observed that within three days after
treatment the dog was normal without any abnor-
malities in the esophagus that was confirmed by ra-
diography and fluoroscopic examination. No
relapse of the disease was observed as much as 1
year after the first visit.  
Discussion
Acquired MG is an immune-mediated condition in
which circulating anti-AChRs antibodies are di-
rected against AChRs in skeletal muscles, inhibit-
ing neurotransmission and accelerating AChRs
exocytosis and degradation (Wray and Sparkes,
2006). The reason that dogs with MG developed
autoantibodies directed against their own AChRs
is unknown (Paciello et al., 2003). Acquired MG
is probably the most common neuromuscular dis-
ease that can be diagnosed and treated in dogs
(Shelton, 2002). Several clinical forms of MG have
been described (Webb et al., 1997). FMG in dogs
has selective involvement of the esophageal skele-
tal muscles and it appears that a similar focal weak-
ness affecting only the extraocular muscles occurs
in human MG. 
The gold standard for the diagnosis of MG is a
demonstration of an increased AChRs antibody
titer (Wray and Sparkes 2006). The sensitivity of
this test is more than 90% and false positive have
not been documented (Moffet, 2007) but the result
of this test takes time so suspecting FMG with
megaoesophagus when excluding the other dis-
eases causing megaesophagus.
Similar to acquire human MG, anti-
choloinesterase drugs form the cornerstone of ther-
apy for acquiring MG in dogs (Shelton 2002),
acting by prolonging the action of acetylcholine at
the neuromuscular junction and enhancing neuro-
muscular transmission. Although pyridostigmine
bromide at the dose of 2 mg/kg was reported for
the treatment of acquired MG with obvious gains
in muscle strength within days of the therapy (Bat-
maz et al. 1998), but we found that it has side effect
by increasing the frequency of the vomiting. This
dose is recommended for generalized MG but not
for FMG. The dosage and schedule of administra-
tion must be tailored to the animal’s needs.
The most important complication of FMG with
megaesophagus is aspiration pneumonia that may
lead to death or euthanasia in most cases. The dogs
with megaesophagus are managed with small, fre-
quent feeding in the upright position and are mon-
itored closely for signs of aspiration pneumonia
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Fig. 2. Clinical and treatment course in case 1 until 241 days. The disappearance of the esophageal dilation and the recovery
of the systolic function of the esophagus was recognized by the fluoroscopy on the 341st day. * Titer of anti-AChRs antibody
at initial presentation (1.04 nmol/L), ** Titer of anti-AChRs antibody on the day 60th, 135th, and 241st (0.4 nmol/L).
(Gaynor et al. 1997; Harvey et al. 1974). The pres-
ent two cases had an only clinical sign of regurgi-
tation without signs of respiratory distress.  
FMG associated with megaesophagus as in the
majority of cases has a variable prognosis for re-
covery. It was reported that many case series of ac-
quired megaesophagus emphasized the frequently
irreversible nature of the condition and poor prog-
nosis (Harvey et al. 1974; Gaynor et al. 1997;
Mears and Denovo 1999). By contrast, Shelton et
al 1990 reported clinical improvement in 48 per-
cent of dogs with megaesophagus due to the focal
form of MG and concluded that early diagnosis of
MG and institution of appropriate therapy may be
important to a successful clinical outcome.
In the follow up of the case 1, despite therapy
with pyridostigmine bromide and the serum AChRs
antibody concentration was normalized after a
short period (60 days) but the clinical remission
was occurred after long time, while in case 2 the
clinical remission was occurred spontaneously after
only 10 days from the onset of the symptoms. Both
dogs are currently not received any immunosup-
pressive therapy and continued to do well. 
Conclusion
We concluded that dogs with megaesophagus due
to acquired FMG, would be resolved sponta-
neously but we can’t predict the time of remission
of the clinical signs. In addition, pyridostigmine
bromide might be helpful in reducing the frequency
of regurgitation although the administered dose
was determined carefully. 
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